Difficulty: Medium
Average Score: 74%
Practice
Which finding would indicate that terazosin has been effective for a patient with BPH?
Correct answer
C
Rationale
Rationale:
The correct answer is C) Improved urinary hesitation. Terazosin is an alpha-1 adrenergic receptor blocker commonly used to treat benign prostatic hyperplasia (BPH). It works by relaxing smooth muscle in the bladder neck and prostate, thereby improving urinary flow and reducing symptoms associated with BPH. Urinary hesitation is a common symptom of BPH where a patient experiences difficulty initiating urination. Therefore, improvement in urinary hesitation would indicate the effectiveness of terazosin in relieving the obstruction caused by an enlarged prostate.
Option A) Decreased prostate size is not typically a direct and immediate effect of terazosin treatment. While the medication may eventually lead to some reduction in prostate size, it is not the primary indicator of its effectiveness in managing BPH symptoms.
Option B) Increased urinary frequency is not a desired outcome in BPH treatment. Terazosin aims to improve urinary flow and reduce the frequency of urination by addressing the obstruction in the urinary tract, so an increase in urinary frequency would not indicate its efficacy.
Option D) Decreased serum PSA levels may be an indicator of response to BPH treatment in the long term, but it is not a direct and immediate measure of terazosin's effectiveness in relieving urinary symptoms such as urinary hesitation.
In an educational context, understanding the specific effects and expected outcomes of pharmacological treatments for BPH is crucial for healthcare professionals managing patients with this condition. Recognizing the appropriate indicators of treatment efficacy helps in monitoring patient progress and adjusting management strategies as needed to optimize outcomes and improve quality of life.
The correct answer is C) Improved urinary hesitation. Terazosin is an alpha-1 adrenergic receptor blocker commonly used to treat benign prostatic hyperplasia (BPH). It works by relaxing smooth muscle in the bladder neck and prostate, thereby improving urinary flow and reducing symptoms associated with BPH. Urinary hesitation is a common symptom of BPH where a patient experiences difficulty initiating urination. Therefore, improvement in urinary hesitation would indicate the effectiveness of terazosin in relieving the obstruction caused by an enlarged prostate.
Option A) Decreased prostate size is not typically a direct and immediate effect of terazosin treatment. While the medication may eventually lead to some reduction in prostate size, it is not the primary indicator of its effectiveness in managing BPH symptoms.
Option B) Increased urinary frequency is not a desired outcome in BPH treatment. Terazosin aims to improve urinary flow and reduce the frequency of urination by addressing the obstruction in the urinary tract, so an increase in urinary frequency would not indicate its efficacy.
Option D) Decreased serum PSA levels may be an indicator of response to BPH treatment in the long term, but it is not a direct and immediate measure of terazosin's effectiveness in relieving urinary symptoms such as urinary hesitation.
In an educational context, understanding the specific effects and expected outcomes of pharmacological treatments for BPH is crucial for healthcare professionals managing patients with this condition. Recognizing the appropriate indicators of treatment efficacy helps in monitoring patient progress and adjusting management strategies as needed to optimize outcomes and improve quality of life.